SEARCH
Home
News
Fortune 500
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Great Place to Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
FORTUNE 500
FORTUNE 500
FORTUNE SEA 500
Fortune 500 Europe
Fortune Global 500
Fortune China 500
Great Place to Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Banking
Investing
Crypto
Leadership
Leadership
Success
Future of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
Angel Adegbesan
Finance
One of the most shorted stocks on the market just leapt 99%, putting a ‘rib-crunching’ squeeze on bearish bettors
By
Angel Adegbesan
,
Carmen Reinicke
, and others
Health
Why a biotech firm’s market value jumped from $3 million to $130 million in a day and is still way up from its ‘almost unfathomably low valuation’
By
Angel Adegbesan
and
Bloomberg
Health
Weight-loss drugs like Ozempic are in such huge demand that spending on them will hit $100 billion by 2035, analyst says
By
Angel Adegbesan
and
Bloomberg
Health
Weight-loss stocks soar up to 15% after obesity-drug study shows an added benefit that may be a ‘huge win’ for future sales
By
Angel Adegbesan
,
Jameelah Robinson
, and others
Finance
The A.I. mania is so red hot that a small $50 million investment from Nvidia sent an obscure biotech firm’s shares up a record 78%
By
Angel Adegbesan
and
Bloomberg